The silence of the disease is its danger
En la última década, Argentina ha logrado reducir en un 26% la mortalidad por cáncer de próstata, un avance que refleja tanto la mejora en las herramientas diagnósticas como un cambio gradual en los hábitos de consulta masculina. Sin embargo, detrás de ese progreso persiste una paradoja antigua: una enfermedad que mata en silencio, en hombres que aún esperan que el dolor les dé permiso para pedir ayuda. La tecnología médica ha avanzado; lo que sigue rezagado es la disposición cultural a cuidarse antes de que sea tarde.
- Más de 11.600 hombres reciben un diagnóstico de cáncer de próstata cada año en Argentina, y muchos llegan al médico cuando la enfermedad ya avanzó.
- La vergüenza, el miedo y la creencia de que solo hay que consultar cuando algo duele siguen empujando a los hombres hacia diagnósticos tardíos.
- Nuevas tecnologías —resonancia multiparamétrica, PET PSMA, biomarcadores genéticos— permiten detectar y tratar el cáncer con una precisión que hace una década era impensable.
- Los protocolos actuales buscan evitar el sobrediagnóstico: un PSA elevado no implica biopsia inmediata, sino repetición del análisis y evaluación del riesgo real.
- La mortalidad cayó de 12,45 a 9,22 muertes por cada 100.000 hombres, pero ese número podría seguir bajando si más hombres consultaran a los 50 años —o a los 40 con antecedentes familiares.
Argentina ha logrado algo que merece atención: la tasa de mortalidad por cáncer de próstata cayó un 26% entre 2014 y 2024, pasando de 12,45 a 9,22 muertes por cada 100.000 hombres. El avance se explica por dos fuerzas que convergieron: más hombres comenzaron a consultar, y los médicos ganaron herramientas diagnósticas mucho más precisas. Resonancias multiparamétricas, estudios PET PSMA y terapias hormonales menos tóxicas transformaron la forma en que se detecta y trata la enfermedad. Aun así, el progreso convive con un problema persistente: muchos hombres llegan tarde, cuando los síntomas ya aparecieron y el cáncer avanzó.
El doctor Gonzalo Vitagliano, del Hospital Alemán de Buenos Aires, señala la paradoja central: el cáncer de próstata en sus etapas tempranas es completamente silencioso. Un hombre puede cargarlo durante años sin sentir nada. Por eso la consulta periódica importa tanto, y esperar el dolor es una estrategia perdedora. La recomendación es clara: todo hombre debería hablar con un urólogo alrededor de los 50 años; a los 40, si tiene antecedentes familiares.
El PSA, el análisis de sangre más utilizado para el tamizaje, es útil pero requiere interpretación cuidadosa. Un valor elevado no significa cáncer: puede deberse a inflamación, infección o actividad física intensa. La guía médica actual indica que, ante un PSA entre 3 y 10 nanogramos por mililitro sin síntomas, lo primero es repetir el análisis antes de avanzar hacia estudios más complejos. Si el riesgo persiste, la resonancia multiparamétrica permite ver la próstata en detalle y, si hay una zona sospechosa, dirigir la biopsia con precisión. La biopsia —único estudio que confirma el cáncer— se reserva para cuando la sospecha está genuinamente fundada.
Pero ningún avance tecnológico alcanza si los hombres no se acercan al sistema. El obstáculo central sigue siendo cultural: la salud prostática permanece envuelta en tabú, vergüenza y la convicción de que consultar es señal de debilidad o de que algo ya está muy mal. Las mujeres normalizaron el control ginecológico hace décadas. Los hombres aún no han hecho lo mismo con su salud urológica. Una consulta no implica biopsia ni tratamiento inmediato; muchas veces empieza con una conversación y un análisis de sangre. La diferencia entre vivir y morir por cáncer de próstata, con frecuencia, no tiene nada que ver con los síntomas —sino con no esperar a que aparezcan.
Argentina has quietly achieved something worth noting: the death rate from prostate cancer has fallen by a quarter over the past decade. Between 2014 and 2024, mortality dropped from 12.45 deaths per 100,000 men to 9.22 per 100,000—a 26% decline that reflects genuine progress in how the disease is caught and treated. Yet this improvement masks a stubborn problem. Men still arrive at urologists too late, often only when symptoms appear, by which time the cancer has already advanced. The information exists. The technology exists. What remains elusive is the willingness to seek it out.
The improvement stems from two converging forces: more men are actually showing up for consultations, and the tools available to doctors have become far more precise. The Argentine Ministry of Health credits advances in diagnostic imaging—multiparametric MRI of the prostate, PET scans with choline, and PET PSMA studies—alongside newer, less toxic hormone therapies and targeted radiation treatments. These are not marginal improvements. They represent a fundamental shift in how prostate cancer is detected and managed. Dr. Gonzalo Vitagliano, head of oncology in the urology service at Hospital Alemán in Buenos Aires, notes that more than 11,600 men receive a prostate cancer diagnosis each year in Argentina. Most have no symptoms beforehand. This is the essential paradox: the disease that kills them often announces itself only after it has become harder to treat.
Prostate cancer in its early stages is silent. A man can harbor it for years without feeling anything wrong. This is why periodic screening matters so much, and why waiting for pain or urinary problems is a losing strategy. The prostate itself is small—roughly the size of a walnut, sitting beneath the bladder—but its health carries outsized weight. Vitagliano recommends that all men begin conversations with a urologist around age 50. For those with a family history of prostate cancer, especially in fathers or brothers, that conversation should start at 40.
The PSA test, which measures a protein in the blood, has become the most common screening tool, but it is also widely misunderstood. An elevated PSA does not mean cancer. It can rise for many reasons: inflammation, infection, benign enlargement, recent sexual activity, intense exercise, or prior medical procedures. Current medical guidance emphasizes a simple but important point: in men without symptoms whose PSA falls between 3 and 10 nanograms per milliliter, the test should be repeated before moving to more complex studies. This repetition can confirm whether the elevation is real or merely a fluctuation, avoiding unnecessary MRIs, biopsies that may not be needed, and the overdiagnosis of conditions that might never have caused actual harm. When PSA remains elevated or a patient's risk profile justifies it, multiparametric MRI becomes increasingly valuable. It allows doctors to see the prostate in detail and, if a suspicious area appears, to direct a biopsy precisely toward the highest-risk zone. If the MRI shows nothing concerning and overall risk is low, a biopsy can sometimes be avoided or delayed, always under medical supervision.
The biopsy itself—the only test that definitively confirms cancer—is invasive, which is why the current approach aims to reserve it for cases where suspicion is genuinely founded rather than ordering it reflexively whenever PSA rises. The digital rectal exam, once central to prostate screening, has receded from routine use in asymptomatic men, though it retains value when symptoms exist, when cancer is suspected, or when a diagnosis is already confirmed and needs clarification.
Beyond PSA and MRI, newer tools have emerged: blood and urine biomarkers, PET PSMA imaging, and tumor genetic studies that reveal not just whether cancer is present but where it is, how aggressive it is, and how far it has spread. These allow for treatment plans tailored to the individual rather than one-size-fits-all protocols. Yet none of this technological progress matters if men do not seek it. The central obstacle remains cultural. Prostate health remains taboo for many men—wrapped in shame, fear of diagnosis, or the belief that consultation is only necessary when something hurts. Women normalized gynecological screening decades ago as routine self-care. Men have not done the same with urological health. Talking about prostate cancer should generate awareness, not alarm. A consultation does not automatically lead to biopsy, imaging, or treatment. Often it begins simply: a conversation and a blood test, after which a doctor decides what comes next.
The message is straightforward: at 50, or at 40 if family history warrants it, a man should speak with a urologist. PSA is a useful tool but must be interpreted thoughtfully. If elevated, repetition often comes first. If risk persists, modern imaging and biomarkers help guide the next step. Biopsy should be reserved for genuine suspicion. The difference between life and death in prostate cancer frequently has nothing to do with symptoms and everything to do with not waiting for them to appear.
Citações Notáveis
The majority of men diagnosed have no previous symptoms, which is why periodic screening is essential to find the disease when it can still be treated with curative intent.— Dr. Gonzalo Vitagliano, head of oncology, Hospital Alemán, Buenos Aires
From age 50 onward, all men should speak with a urologist about their screening. If there is a family history of prostate cancer, especially in fathers or close relatives, that conversation should begin around age 40.— Dr. Gonzalo Vitagliano
A Conversa do Hearth Outra perspectiva sobre a história
Why did mortality drop so sharply over just ten years? That's not a small shift.
Better detection caught more cancers early, when they're still curable. But also—and this matters—doctors got smarter about which men actually needed aggressive intervention. They stopped treating every elevated PSA like an emergency.
So the technology improved, but so did the thinking?
Exactly. An MRI can now show whether a suspicious PSA reading is real or noise. That spares men from unnecessary biopsies. You're treating the right people, not everyone.
Then why do you say men still arrive too late?
Because knowing what to do and actually doing it are different things. A man has to walk into a doctor's office first. Shame, fear, denial—these are stronger than statistics.
Is the PSA test the problem, then? I've heard it oversells itself.
It's not a diagnosis. It's a signal. The problem was treating it like one. Now doctors repeat it, use imaging to clarify, and only biopsy when there's real reason. That's more honest.
What changes if a man actually shows up at 50?
Everything. Early prostate cancer has no symptoms. You find it by looking, not by waiting to feel pain. Once you find it early, you can often cure it. That's the whole story.
And if he waits until something hurts?
By then it's often spread. Harder to treat, worse outcomes. The silence of the disease is its danger.